Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to $8.0 million.

  • Stoke Therapeutics' Gains from Investment Securities rose 10.97% to $809,300 in Q3 2025 from the same period last year, while for Sep 2025 it was $809,300, marking a year-over-year increase of 10.97%. This contributed to the annual value of $8.0 million for FY2024, which is 23.41% up from last year.
  • As of FY2024, Stoke Therapeutics' Gains from Investment Securities stood at $8.0 million, which was up 23.41% from $6.5 million recorded in FY2023.
  • Stoke Therapeutics' Gains from Investment Securities' 5-year high stood at $27.3 million during FY2020, with a 5-year trough of $6.5 million in FY2023.
  • In the last 3 years, Stoke Therapeutics' Gains from Investment Securities had a median value of $8.0 million in 2024 and averaged $7.6 million.
  • In the last 5 years, Stoke Therapeutics' Gains from Investment Securities surged by 160.00% in 2020 and then slumped by 63.74% in 2021.
  • Stoke Therapeutics' Gains from Investment Securities (Yearly) stood at $27.3 million in 2020, then slumped by 63.74% to $9.9 million in 2021, then declined by 16.42% to $8.3 million in 2022, then decreased by 21.71% to $6.5 million in 2023, then rose by 23.41% to $8.0 million in 2024.